Efficacy and Safety of Different Doses of Rivaroxaban in Elderly Chinese Patients With Nonvalvular Atrial Fibrillation

Sex: All

Ages: 75 Years – N/A

Enrollment: 300

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Summary

From January 2023 to December 2025, 300 elderly patients with nonvalvular atrial fibrillation in Drum Tower Hospital Affiliated to Medical Scholl of Nanjing University will be enrolled to compare the efficacy and safety of rivaroxaban-H, rivaroxaban-M and rivaroxaban-L dose in elderly patients after 24-month follow-up.

Eligibility Criteria

Inclusion Criteria:Age≥75 yearsChinese patient: male or femalePatients had to be diagnosed as nonvalvular atrial fibrillation (NVAF)Exclusion Criteria:Patients with anemia (hemoglobin<100g/L), known human immunodeficiency virus infection, female patients who were pregnant or lactating and patients for whom warfarin was contraindicated, were also excludedPatients with calculated creatine clearance vulue<30ml/minPatients expected to chronically use a non-steroidal anti-inflammatory agent (except for external preparations) and those treated with a strong cytochrome P4503A4 inhibitor (eg, ketoconazole, clarithromycin, or protease inhibitors) or a strong cytochrome P450 3A4 inducer (eg, rifampicin) during the trial

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05638100). StuddyBuddy aggregates publicly available trial information.